The effect of fibrinolysin ointment in the treatment of burn scars: A narrative review article
Main Article Content
Abstract
Burn injuries are a significant global health concern, ranking among the most common causes of trauma and leading to severe physical, functional, and psychosocial consequences. Effective burn wound management aims not only to promote healing but also to minimize scarring, infection, and long-term complications. Fibrinolysin ointment, a topical enzymatic agent containing proteolytic enzymes such as fibrinolysin, deoxyribonuclease, and trypsin, has been investigated as a treatment option for improving burn wound outcomes. This narrative review explores the potential therapeutic benefits, mechanisms of action, clinical applications, and limitations of fibrinolysin ointment in the context of burn injuries. Fibrinolysin functions primarily through enzymatic debridement, dissolving necrotic tissue, facilitating wound cleansing, reducing bacterial colonization, and stimulating tissue regeneration. Its anti-inflammatory properties also help reduce edema and local pain, creating a favorable microenvironment for re-epithelialization and collagen remodeling. Several animal studies suggest its usefulness in promoting faster healing in second- and third-degree burns. However, the results are often less favorable when compared to more aggressive enzymatic agents or natural alternatives, such as kiwi extract or honey. While fibrinolysin has shown promise in reducing healing time and indirectly improving scar quality, there is a lack of robust human clinical trials assessing its long-term effects on scar formation, particularly through the use of standardized scar assessment scales. Although generally safe with minimal side effects, fibrinolysin ointment may cause localized irritation or hypersensitivity in some patients. This review concludes that while fibrinolysin may serve as a supportive treatment in burn care, especially in superficial wounds, further clinical research is warranted to validate its efficacy, optimize its usage, and establish its role in multidisciplinary burn scar management protocols.
Article Details
Section

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
References
[1] Greenhalgh DG. Management of Burns. N Engl J Med. 2019;380(24):2349-2359. DOI: 10.1056/NEJMra1807442 PMID: 31189038
[2] Alcalá-Cerrillo M, González-Sánchez J, González-Bernal JJ, Santamaría-Peláez M, Fernández-Solana J, Sánchez Gómez SM, et al. Retrospective Study of the Epidemiological-Clinical Characteristics of Burns Treated in a Hospital Emergency Service (2018-2022). Nurs Rep. 2024;14(3):1987-1997.
DOI: 10.3390/nursrep14030148 PMID: 39189278
[3] Żwierełło W, Piorun K, Skórka-Majewicz M, Maruszewska A, Antoniewski J, Gutowska I. Burns: Classification, Pathophysiology, and Treatment: A Review. Int J Mol Sci. 2023;24(4):3749. DOI: 10.3390/ijms24043749 PMID: 36835171
[4] Yakupu A, Zhang J, Dong W, Song F, Dong J, Lu S. The epidemiological characteristic and trends of burns globally. BMC Public Health. 2022;22(1):1596. DOI: 10.1186/s12889-022-13887-2 PMID: 35996116
[5] van den Bosch AS, Verwilligen RAF, Pijpe A, Bosma E, van der Vlies CH, Lucas Y, et al. Outcomes of dermal substitutes in burns and burn scar reconstruction: A systematic review and meta-analysis. Wound Repair Regen. 2024;32(6):960-978.
DOI: 10.1111/wrr.13226 PMID: 39435560
[6] Ladhani HA, Yowler CJ, Claridge JA. Burn Wound Colonization, Infection, and Sepsis. Surg Infect (Larchmt). 2021;22(1):44-48. DOI: 10.1089/sur.2020.346 PMID: 33085576
[7] D'Abbondanza JA, Shahrokhi S. Burn Infection and Burn Sepsis. Surg Infect (Larchmt). 2021;22(1):58-64.
DOI: 10.1089/sur.2020.102 PMID: 32364824
[8] Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P, Herndon DN. Hypertrophic scarring: the greatest unmet challenge after burn injury. Lancet. 2016;388(10052):1427-1436.
DOI: 10.1016/S0140-6736(16)31406-4 PMID: 27707499
[9] van Baar ME, Essink-Bot ML, Oen IM, Dokter J, Boxma H, van Beeck EF. Functional outcome after burns: a review. Burns. 2006;32(1):1-9. DOI: 10.1016/j.burns.2005.08.007
PMID: 16376020
[10] Ghahghai M, Ghorbani SS, Hoseininejad S, Sheikhi A, Farhadi M, Rahbar R. Factors responsible for mortality among burns patients in Islamic Republic of Iran. East Mediterr Health J. 2023;29(8):650-656. DOI: 10.26719/emhj.23.092
PMID: 37698220
[11] Bayuo J, Wong FKY, Lin R, Su JJ, Abu-Odah H. A meta-ethnography of developing and living with post-burn scars. J Nurs Scholarsh. 2023;55(1):319-328. DOI: 10.1111/jnu.12811
PMID: 36161474
[12] Hirche C, Citterio A, Hoeksema H, Koller J, Lehner M, Martinez JR, et al. Eschar removal by bromelain based enzymatic debridement (Nexobrid®) in burns: An European consensus. Burns. 2017;43(8):1640-1653.
DOI: 10.1016/j.burns.2017.07.025 PMID: 29033046
[13] Schulz A, Perbix W, Shoham Y, Daali S, Charalampaki C, Fuchs PC, et al. Our initial learning curve in the enzymatic debridement of severely burned hands-Management and pit falls of initial treatments and our development of a post debridement wound treatment algorithm. Burns. 2017;43(2):326-336.
DOI: 10.1016/j.burns.2016.08.009 PMID: 28341257
[14] Rosenberg L, Krieger Y, Bogdanov-Berezovski A, Silberstein E, Shoham Y, Singer AJ. A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT. Burns. 2014;40(3):466-74.
DOI: 10.1016/j.burns.2013.08.013 PMID: 24074719
[15] Abdul Rahim P, Rengaswamy D. Fibrinolytic Enzyme - An Overview. Curr Pharm Biotechnol. 2022;23(11):1336-1345. DOI: 10.2174/1389201023666220104143113 PMID: 34983344
[16] Püllen R, Popp R, Volkers P, Füsgen I. Prospective randomized double-blind study of the wound-debriding effects of collagenase and fibrinolysin/deoxyribonuclease in pressure ulcers. Age Ageing. 2002;31(2):126-30. DOI: 10.1093/ageing/31.2.126 PMID: 11937475
[17] Schulz A, Schiefer JL, Fuchs PC, Kanho CH, Nourah N, Heitzmann W. Does Platelet-Rich Fibrin Enhance Healing Of Burn Wounds? Our First Experiences And Main Pitfalls. Ann Burns Fire Disasters. 2021;34(1):42-52. PMID: 34054386
[18] HARDAWAY RM, BURNS JW. Mechanism of action of fibrinolysin in the prevention of irreversible hemorrhagic shock. Ann Surg. 1963;157(2):305-9. DOI: 10.1097/00000658-196302000-00020 PMID: 13952731
[19] Kooshiar H, Abbaspour H, Motamed Al Shariati SM, Rakhshandeh H, Khajavi Rad A, Esmaily H, et al. Topical effectiveness of kiwifruit versus fibrinolysin ointment on removal of necrotic tissue of full-thickness burns in male rats. Dermatol Ther. 2012;25(6):621-5. DOI: 10.1111/j.1529-8019.2012.01541.x PMID: 23210763
[20] Biondo-Simões MLP, Henning Júnior L, Boen BRO, Prado JLD, Costa LRD, Robes RR, et al. Comparative analysis of the effects of honey, copaiba oil-resin and a commercial product (fibrinolysin, deoxyribonuclease and chloramphenicol) on second intention healing, in rats. Rev Col Bras Cir. 2019;46(5):e20192245. DOI: 10.1590/0100-6991e-20192245 PMID: 31778393
[21] Kooshiar H, Abbaspour H, Motamed Al Shariati SM, Rakhshandeh H, Khajavi Rad A, Esmaily H, et al. Topical effectiveness of kiwifruit versus fibrinolysin ointment on removal of necrotic tissue of full-thickness burns in male rats. Dermatol Ther. 2012;25(6):621-5. DOI: 10.1111/j.1529-8019.2012.01541.x PMID: 23210763
 
							 
						 
            
         
             
            